Adherencia al Tratamiento Inmunosupresor en Pacientes Trasplantados Renales en una Institución de Salud de la Ciudad de Corrientes, entre 2018-2023.

Objective: This research aimed to describe adherence to immunosuppressive treatment in kidney transplant patients.Material and methods: Quantitative, descriptive, cross-sectional and observational study. Population: Kidney transplant recipients assisted in a health institution in the city of Corrientes, in the period from March 2018 to March 2023. A questionnaire was used based on 2 measurement scales, ITAS and ITBS. The information collected was analyzed using an Excel computer program. 23 kidney transplant patients were surveyed.Results: 92% adhered to immunosuppressive treatment, the average age was 43 years and 57% were female. With respect to the variable that evaluates uncontrollable barriers to adherence to immunosuppressive treatment in the last three months, it is relevant to highlight that 87% of the participants report a decrease in these barriers, and in relation to the variable on controllable barriers that perceived by patients to adhere to immunosuppressive treatment in the last 3 months, it was observed that 100% of those surveyed have a lower presence of controllable barriers. Finally, adherence to immunosuppressive treatment according to age and sex. Conclusion: High adherence to immunosuppressive treatment in kidney transplantation is highlighted, 92% of participants. Improvement in uncontrollable barriers suggests positive progress in treatment management. Although there are divergences with other studies, the minimal perception of controllable barriers indicates a general commitment of patientsConclusions: Platelet-rich plasma is an effective and safe method to accelerate healing, reduce the area of ulcers and reduce pain in patients. Furthermore, this therapy does not increase bacteriological growth or microbial load in chronic venous ulcers.